Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes

BACKGROUND: Immunotherapy with CTLA-4 inhibitors and PD1 checkpoint inhibitors has initiated a breakthrough in the treatment and prognosis of patients with metastatic melanoma. The survival of these patients has increased from the expected survival time of less than 12 months to at least forty month...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesti, Tanja, Ceplak Mencin, Vid, Mileva Boshkoska, Biljana, Ocvirk, Janja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366732/
https://www.ncbi.nlm.nih.gov/pubmed/33939899
http://dx.doi.org/10.2478/raon-2021-0019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366732/
https://www.ncbi.nlm.nih.gov/pubmed/33939899
http://dx.doi.org/10.2478/raon-2021-0019

Ejemplares similares